MTAP Biomarker Screening for STING Agonist Cancer Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge is to identify which cancer patients are suitable for STING agonists, as current methods do not accurately determine patient suitability, leading to potential ineffective treatments.
Innovation Solution
Detect the expression level of S-methyl-5′-thioadenosine phosphorylase (MTAP) in cancer patients using specific probes, and predict susceptibility to STING agonists based on MTAP expression levels, providing targeted treatment with STING agonists for high-expressers and alternative treatments for low-expressers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If STING agonists are administered to cancer patients without prior susceptibility assessment, then treatment coverage is maximized, but treatment effectiveness is reduced due to administration to unsuitable patients
Solution Approach 1:
The patent performs MTAP expression level detection before administering STING agonists to predict patient susceptibility in advance. This preliminary assessment identifies suitable patients beforehand, ensuring treatment effectiveness while avoiding unnecessary treatments for unsuitable patients, thus resolving the contradiction between treatment coverage and effectiveness.
2Measurement precision
If MTAP expression detection is performed for all cancer patients before STING agonist treatment, then treatment suitability is accurately identified, but diagnostic time and cost increase
Solution Approach 1:
The patent employs fluorescence in situ hybridization (FISH) technology with specific probes to detect MTAP expression levels. FISH is a well-established, relatively quick, and cost-effective molecular cytogenetic technique that can be performed on routine tissue samples, providing accurate susceptibility prediction without excessive time or resource investment.
3Productivity
If STING agonists are administered to patients with low MTAP expression, then more patients receive treatment, but treatment response is significantly reduced
Solution Approach 1:
The patent applies different treatment strategies based on local characteristics of patient tumor tissue - specifically, MTAP expression status. Patients with high MTAP expression receive STING agonist treatment with high expected efficacy, while patients with low MTAP expression are directed to alternative treatments. This personalized approach optimizes both treatment coverage and response rates by matching treatment to patient-specific characteristics.
Data Source
AI summary
A method for predicting susceptibility to stimulator of interferon genes (STING) agonists of a cancer patient is provided, comprising (1) obtaining at least one sample from the cancer patient; (2) detecting an expression level of S-methyl-5′-thioadenosine phosphorylase (MTAP) in the at least one sample by using at least one specific probe; and (3) if MTAP is expressed in the at least one sample, then predicting that the cancer patient has high-susceptibility to STING agonists and providing STING agonists to treat the cancer patient; otherwise providing non-STING agonists for treatment.